摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,6R,7S,8S)-7-[(E)-丁-1-烯-3-炔基]-2-[(E)-戊-2-烯-4-炔基]-1-氮杂螺[5.5]十一烷-8-醇 | 34272-51-0

中文名称
(2S,6R,7S,8S)-7-[(E)-丁-1-烯-3-炔基]-2-[(E)-戊-2-烯-4-炔基]-1-氮杂螺[5.5]十一烷-8-醇
中文别名
——
英文名称
(-)-histrionicotoxin
英文别名
l-histrionicotoxin;histrionicotoxin;(-)-HTX;(2S,6R,10S,11S)-11-[(Z)-but-1-en-3-ynyl]-2-[(Z)-pent-2-en-4-ynyl]-1-azaspiro[5.5]undecan-10-ol
(2S,6R,7S,8S)-7-[(E)-丁-1-烯-3-炔基]-2-[(E)-戊-2-烯-4-炔基]-1-氮杂螺[5.5]十一烷-8-醇化学式
CAS
34272-51-0
化学式
C19H25NO
mdl
——
分子量
283.414
InChiKey
JBRYWENFVHQBGY-AFVFYVOOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    75-76°
  • 比旋光度:
    D20 -112° (c = 0.34 in ethanol)
  • 沸点:
    411.1±35.0 °C(Predicted)
  • 密度:
    1.05±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    32.3
  • 氢给体数:
    2
  • 氢受体数:
    2

ADMET

毒理性
  • 毒性总结
戏剧性毒素是一种强烈的非竞争性尼古丁乙酰胆碱受体的拮抗剂。
Histrionicotoxin is a potent non-competitive antagonist of nicotinic acetylcholine receptors. (L1072)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 致癌物分类
对人类不具有致癌性(未被国际癌症研究机构IARC列名)。
No indication of carcinogenicity to humans (not listed by IARC).
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 健康影响
戏剧性毒素是神经毒性的。
Histrionicotoxin is neurotoxic. (L1072)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 暴露途径
注射(刺伤/咬伤)(L1811);吸入(吸烟)(L1810)
Injection (sting/bite) (L1811) ; inhalation (smoking) (L1810)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 症状
戏剧毒素是神经毒性的。
Histrionicotoxin is neurotoxic. (L1072)
来源:Toxin and Toxin Target Database (T3DB)

SDS

SDS:5d0914979726831f4c4e00bd7563e4a8
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Total Synthesis of (−)-Histrionicotoxin
    作者:Yohei Adachi、Noriyuki Kamei、Satoshi Yokoshima、Tohru Fukuyama
    DOI:10.1021/ol2018032
    日期:2011.8.19
    A total synthesis of ()-histrionicotoxin was achieved. Our synthesis features preparation of a pseudosymmetrical dienyne through chirality transfer from an allenylsilane, a dienyne metathesis to produce the bicyclo [5.4.0] system in optically active form, selective functionalization of a diene via a 5-exo-trig iodoetherification, and an asymmetric propargylation.
    (-)-histrionicotoxin的总合成得以实现。我们的合成方法包括通过从烯丙基硅烷中手性转移制备拟对称的二烯炔,二烯炔复分解以产生光学活性形式的双环[5.4.0]系统,通过5-exo-trig碘醚化对二烯进行选择性官能化以及不对称炔丙基化。
  • Correction to Total Synthesis of (−)-Histrionicotoxin
    作者:Yohei Adachi、Noriyuki Kamei、Satoshi Yokoshima、Tohru Fukuyama
    DOI:10.1021/ol5001632
    日期:2014.2.21
    Solvent peaks had been removed from the 1H NMR spectra reported for compounds 8, 12, S3, and S10. Peaks of impurities had been removed from the 1H NMR spectra reported for compounds 6 and S18. Original FIDs were located, and the spectra were reprocessed and have been replaced for the above compounds in the revised Supporting Information submitted with this correction. The spectra editing did not affect
    从溶剂峰已被除去1 1 H NMR谱报告化合物8,12,S3,和S10。已从报道的化合物6和S18的1 H NMR光谱中除去了杂质峰。找到了原始的FID,并对光谱进行了重新处理,并已在通过此更正提交的修订的《支持信息》中替换了上述化合物。光谱编辑不会影响已发表论文的任何结论。根据修订后的光谱和校正的产率计算出的纯度如下:8(纯度95%,产率91%),12(纯度95%,产率92%),S3(纯度97%,产率88%)和S10(纯度96%,产率86%)。包含在杂质6是三Ñ丁基膦和乙醇,纯度和产率计算为58%的纯度和修订后的频谱的基础上产率为50%。S18的样品中含有一些未知杂质。因此,无法确定确切的纯度。修订后的支持信息,包括重新处理的光谱。可通过Internet(http://pubs.acs.org)免费获得此材料。这篇文章被1个出版物引用。修订后的支持信息,包括重新处理的光谱。可通过Internet(http://pubs
  • Total Synthesis of (−)-Histrionicotoxin through a Stereoselective Radical Translocation-Cyclization Reaction
    作者:Manabu Sato、Hiroki Azuma、Akihiro Daigaku、Sota Sato、Kiyosei Takasu、Kentaro Okano、Hidetoshi Tokuyama
    DOI:10.1002/anie.201609941
    日期:2017.1.19
    Stereoselective total syntheses of ()‐histrionicotoxin and ()‐histrionicotoxin 235A are described. The 1‐azaspiro[5.5]undecane skeleton was constructed diastereoselectively by a radical translocation–cyclization reaction involving a chiral cyclic acetal; the use of tris(trimethylsilyl)silane was crucial for the high diastereoselectivity. The cyclization product was converted into ()‐histrionicotoxin
    描述了(-)-histrionicotoxin和(-)-histrionicotoxin 235A的立体选择性全合成。1-azaspiro [5.5]十一烷骨架是通过涉及手性环缩醛的自由基易位环化反应非对映选择性地构建的;三(三甲基甲硅烷基)硅烷的使用对于高非对映选择性至关重要。通过含未保护内酰胺的衍生物的一锅部分还原烯丙基化反应,环化产物转化为(-)-histrionicotoxin 235A。最后,将两个末端烯烃转化为烯炔,并以1,3-氨基醇作为氧杂噻唑烷氧化物进行保护,以完成(-)-组蛋白毒素的全部合成。
  • ENZYME INHIBITING COMPOUNDS AND METHODS
    申请人:The Board of Trustees of the University of Illinois
    公开号:US20140100198A1
    公开(公告)日:2014-04-10
    The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe 4 S 4 cluster of an isoprenoid biosynthesis enzyme.
    本发明提供了化合物、组合物和方法,用于研究Rohmer途径和治疗细菌感染或寄生虫感染。寄生虫感染可以是原虫感染,例如疟疾。这些化合物和组合物也可以用作抗生素,例如杀死细菌或寄生虫,或抑制细菌或寄生虫的生长。本发明还提供异戊二烯生物合成酶的抑制剂,以及抑制异戊二烯生物合成酶活性的方法。这些化合物可以是例如炔烃或联烯,它们与异戊二烯生物合成酶的Fe4S4簇的独特Fe结合。
  • Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
    申请人:Acino AG
    公开号:EP2559427A1
    公开(公告)日:2013-02-20
    Die Erfindung betrifft ein transdermales therapeutisches System (TTS) mit einem Gehalt an mindestens einem Modulator für nikotinische Acetylcholinzrezeptoren (nAChR-Modulator).
    本发明涉及一种含有至少一种烟碱乙酰胆碱受体调节剂(nAChR 调节剂)的透皮治疗系统(TTS)。
查看更多

同类化合物

桥虫毒素 7-[(1Z)-1,3-丁二烯基]-2-[(2Z)-2-戊烯-4-炔基]-1-氮杂螺[5.5]十一烷-8-醇 (2S,6R,7S,8S)-7-[(E)-丁-1-烯-3-炔基]-2-[(E)-戊-2-烯-4-炔基]-1-氮杂螺[5.5]十一烷-8-醇 (2R,6R,7alpha,8beta)-7-[(Z)-1-丁烯-3-炔基]-2-(4-戊炔基)-1-氮杂螺[5.5]十一烷-8-醇 12-(4-chlorobut-1-en-3-ynyl)-5-(5-chloropent-2-en-4-ynyl)-7-oxa-6-azatricyclo[6.3.1.01,6]dodecane 6,8.0]undecane">(2S,6R,7S,8S)-(2'Z, 1"Z)-2-(penta-2',4'-dienyl)-7-(4''-triisopropylsilyl-but-1''-en-3''-yn-1''-yl)-1-aza-12-oxatricyclo[5.4.16,8.0]undecane (-)-histrionicotoxin 285E 6,8.0]undecane">(2S,6R,7S,8S)-2-(prop-2'-enyl)-7-(4"-triisopropylsilyl-but-1"-en-3"-yn-1"-yl)-1-aza-12-oxatricyclo[5.4.16,8.0]undecane (-)-histrionicotoxin 259A 2,7-epi-(+/-)-Perhydrohistrionicotoxin isodihydrohistrionicotoxin allodihydrohistrionicotoxin 6,8.0]undecane">(2S,6R,7S,8S)-(1"Z)-2-(5'-trimethylsilylpent-4'-ynl)-7-(4''-trimethylsilyl-but-1''-en-3''-yn-1''-yl)-1-aza-12-oxatricyclo[5.4.16,8.0]undecane Octahydrohistrionicotoxin (±)-perhydrogephyrotoxin (±)-gephyrotoxin dl-dihydrogephyrotoxin 2-[(1R,3aR,5aR,6R,9aS)-6-[(Z)-pent-2-en-4-ynyl]-1,2,3,3a,4,5,5a,6,7,8,9,9a-dodecahydropyrrolo[1,2-a]quinolin-1-yl]ethyl 4-bromobenzoate (2S,6R,7S,8S)-(1'Z)-2-cyanomethyl-7-(but-1'-en-3'-yn-1'-yl)-1-aza-12-oxatricyclo [5.4.16,8.0]undecane 2-[(1S,3aS,5aS,6S,9aR)-((E)-6-Pent-2-en-4-ynyl)-dodecahydro-pyrrolo[1,2-a]quinolin-1-yl]-ethanol benzyl (1'S,3'R,4R,5R,6'S,8'S)-5'-oxo-3'-pentyl-4,5-diphenyl-7'-propylspiro[1,3-dioxolane-2,9'-2-azatricyclo[6.4.0.01,6]dodecane]-2'-carboxylate benzyl (2R,3R,6S,7S,9R)-6-butyl-11-oxo-9-pentyl-2,3-diphenyl-1,4-dioxa-8-azadispiro[4.1.57.35]pentadecane-8-carboxylate 2-(6-[(2Z)-2,4-Pentadienyl]dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethanol Histrionicotoxin 285b delta-17-trans-Histrionicotoxin 283a' 2-((1S,3aS,5aS,6S,9aR)-6-((Z)-Pent-2-en-4-yn-1-yl)dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethanol (2R,6R,7S,8S)-7-((Z)-But-1-en-1-yl)-2-pentyl-1-azaspiro[5.5]undecan-8-ol Histionicotoxin 285c 2-(6-[(2E)-2-Penten-4-ynyl]dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethyl 4-bromobenzoate Dihydrohistrionicotoxin 285e Isotetrahydrohistrionicotoxin 287a (2S,6R,7S,8S)-2-Allyl-7-((Z)-but-1-en-3-yn-1-yl)-1-azaspiro[5.5]undecan-8-ol 11-[(1E)-buta-1,3-dienyl]-2-prop-2-enyl-1-azaspiro[5.5]undecan-10-ol Tetrahydrohistrionicotoxin 287b (2R,6R,7S,8S)-7-(But-3-en-1-yl)-2-(pent-4-en-1-yl)-1-azaspiro[5.5]undecan-8-yl acetate (2S,6R,7S,8S)-7-((Z)-But-1-en-3-yn-1-yl)-2-((Z)-pent-2-en-4-yn-1-yl)-1-azaspiro[5.5]undecan-8-ol (2S,6R,7S,8S)-2-Allyl-7-((Z)-buta-1,3-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol (2S,6R,7S,8S)-7-((Z)-But-1-en-3-yn-1-yl)-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol (2S,6R,10S,11S)-11-but-1-en-3-ynyl-2-prop-2-enyl-1-azaspiro[5.5]undecan-10-ol 2-(6-pent-2-en-4-ynyl-1,2,3,3a,4,5,5a,6,7,8,9,9a-dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethyl 4-bromobenzoate (2S,6R,7S,8S)-(1'Z)-2-(cyanomethyl)-7-(4'-triisopropylsilyl-but-1'-en-3'-yn-1'-yl)-1-aza-12-oxatricyclo[5.4.16,8.0]undecane Allodihydrobistrionicotoxin 11-Buta-1,3-dienyl-2-pent-4-ynyl-1-azaspiro[5.5]undecan-10-ol 2-(6-Penta-2,4-dienyl-1,2,3,3a,4,5,5a,6,7,8,9,9a-dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethanol 11-But-1-en-3-ynyl-2-prop-2-enyl-1-azaspiro[5.5]undecan-10-ol (+/-)-Octahydrohistrionicotoxin 11-Buta-1,3-dienyl-2-prop-2-enyl-1-azaspiro[5.5]undecan-10-ol 7-but-1-en-3-ynyl-2-pent-2-en-4-ynyl-1-aza-spiro[5.5]undecan-8-ol 2-(6-Pent-2-en-4-ynyl-1,2,3,3a,4,5,5a,6,7,8,9,9a-dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethanol